Gleave M - Search Results

1

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

2

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M. Bruchovsky N, et al. Among authors: gleave m. Urologe A. 1995 Sep;34(5):389-92. Urologe A. 1995. PMID: 7483155 Review. German.

3

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

4

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

5

Control of tumor progression by maintenance of apoptosis.

Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M. Bruchovsky N, et al. Among authors: gleave m. Prostate Suppl. 1996;6:13-21. Prostate Suppl. 1996. PMID: 8630223 Review.

6

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD. Gleave ME, et al. Urology. 1996 May;47(5):708-12. doi: 10.1016/s0090-4295(96)80016-1. Urology. 1996. PMID: 8650870

7

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD. Goldenberg SL, et al. Among authors: gleave me. Urology. 1996 Jun;47(6):882-4. doi: 10.1016/S0090-4295(96)00048-9. Urology. 1996. PMID: 8677581 Clinical Trial.

8

Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.

Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Rabbani F, et al. Among authors: gleave me. Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394

9

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

10

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

694 results

Search Page

Filters